Kornimate/medical-research-clean huggingface dataset:
china structural ventricular arrhythmias registry

Conditions: Ventricular Arrythmia

Summary: this is an observational, prospective, multi-center registry ,aiming at building a risk stratification for malignant structural ventricular arrhythmias. 2000 participants will be recruited from 10 centers in china,with clinical data to be abstracted from medical records ,and blood samples to be collected for finding promising risk indicators.the follow-up should be made every 6 mouths.

in china, the prevalence and risk factors of malignant ventricular arrhythmias remain unclear. in addition ,the mainstream treatment relies on implantable devices and medication.china malignant ventricular arrhythmias study is a nation-wide complex consisting of several interrelated studies, with the aim of building a risk stratification as well as a efficient and economic strategy for early prevention and treatment. structural ventricular arrhythmias registry, as a part of china malignant ventricular arrhythmias study, is an observational, prospective, multi-center registry, aiming at building a risk stratification for malignant structural ventricular arrhythmias. 2000 patients with definitive diagnosis will be recruited consecutively from 10 major arrhythmia centers distributed in 6 areas in china. at study entry, participants will be interviewed and asked to sign the informed consent. demographic characteristics, medical history, clinical features, laboratory tests, imaging pictures, medications, procedures, and in-hospital outcomes of patients will be abstracted from medical records by well trained staffs .at the same time, blood samples will be collected to detect biological markers, like genes, inflammatory factors ,etc. once enrolled, the participants will receive follow up every 6 mouths about condition of arrhythmia, medication, clinical events, etc.

Eligibility criteria:
inclusion criteria: * diagnosed as ventricular arrhythmia resulted by structural heart diseases, including ischemic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, etc. exclusion criteria: * none

Keywords: structural ventricular arrythmia ischemic cardiomyopathy arrhythmogenic right ventricular cardiomyopathy dilated cardiomyopathy hypertrophic cardiomyopathy risk stratification
permeability mri in cerebral cavernous malformations type 1 in new mexico: effects of statins

Conditions: Cavernous Angioma, Familial; Cerebral Cavernous Malformations; Cerebral Cavernous Hemangioma

Summary: cerebral cavernous malformations (ccms) are clusters of abnormal blood vessels in the brain and spine. ccms can bleed and cause strokes, seizures, and headaches. in some patients, ccms affect the blood brain barrier (bbb). the bbb is the body's separation of blood and its contents in the brain from the brain tissue itself. abnormal leakiness or permeability of this barrier can cause disease. we will measure the permeability (leakiness) of the bbb using a magnetic resonance imaging (mri) technique called dynamic contrast-enhanced mri (dcemri). the purpose of this study is to look at whether statin medications change the permeability (leakiness) of the blood brain barrier in ccm patients. statin medications are used to lower cholesterol levels and prevent heart attack and stroke. in addition, this medication may decrease the risk of brain hemorrhage or bleeding in patients with ccm. this study will examine whether the permeability of the bbb changes following the administration of simvastatin for three months.


Eligibility criteria:
inclusion criteria: * diagnosis of cerebral cavernous malformations-common hispanic mutation (ccm1-chm) * must be willing to travel to the university of new mexico in albuquerque, nm for 5 visits over the course of three months. exclusion criteria: * incarceration * unable to pass mri safety screening (pregnant females, claustrophics, or those with certain metallic items implanted in their bodies) * low kidney function or transplants, an egfr below 60 ml/min * currently taking statin medications or have taken statin medications in the past 6 months * known allergy or intolerance to statins * known allergy or intolerance to gadolinium * liver dysfunction at baseline, ast \> 47 and/or alt \> 49 * consumption of large quantities of alcohol, men who consume more than 2 daily drinks and women who consume more than one daily drink * ck level of 232 or higher * triglycerides greater than or equal to 500. * medications: gemfibrozil, cyclosporine, danazol, itraconazole, ketoconazole, posaconazole, ethromycin, clarithomycin, telithromycin, hiv protease inhibitors, nefazoldone, amiodarone, verapamil, dilitiazem, amlodipine, or ranalazine

Keywords: hispanic
safety and efficacy of bcma-targeted car-t therapy for relapsed/refractory multiple myeloma

Conditions: Multiple Myeloma; Multiple Myeloma in Relapse; Neoplasm, Plasma Cell

Summary: this is a single arm study to evaluate the efficacy and safety of bcma-targeted car-t cells therapy for patients with relapsed/refractory multiple myeloma.

there are limited options for treatment of relapse/refractory multiple myeloma. bcma is expressed on most multiple myeloma cells so it is an ideal target for car-t. in this study, investigators will evaluate the safety and efficacy of car-t targeting bcma in patients with relapsed/refractory multiple myeloma. the primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent 2. diagnose as relapsed /refractory multiple myeloma, and meet one of the following conditions: 1. failed to standard chemotherapy regimens; 2. relapse after complete remission, high-risk and / or refractory patients ; 3. relapse after hematopoietic stem cell transplantation; 3. evidence for cell membrane bcma expression； 4. all genders, ages: 18 to 75 years； 5. the expect time of survive is above 12 weeks; 6. kps\>60； 7. no serious mental disorders ; 8. left ventricular ejection fraction ≥50% 9. sufficient hepatic function defined by alt/ast≤3 x uln and bilirubin≤2 x uln; 10. sufficient renal function defined by creatinine clearance≤2 x uln; 11. sufficient pulmonary function defined by indoor oxygen saturation≥92%; 12. with single or venous blood collection standards, and no other cell collection contraindications; 13. ability and willingness to adhere to the study visit schedule and all protocol requirements. exclusion criteria: 1. have received car-t therapy or other genetically modified cell therapy before screening； 2. participated in other clinical research within 1 month before screening； 3. have received the following anti-tumor treatment before screening: have received chemotherapy, targeted therapy or other experimental drug treatment within 4 weeks, except those who have confirmed disease progression after treatment; 4. live attenuated vaccine within 4 weeks before screening; 5. convulsion or stoke within past 6 months; 6. previous history of other malignancy; 7. presence of uncontrolled active infection; 8. subjects with positive hbsag or hbcab positive and peripheral blood hbv dna titer is higher than the lower limit of detection of the research institution; hcv antibody positive and peripheral blood hcv rna titer is higher than the lower limit of detection of the research institution; hiv antibody positive; syphilis primary screening antibody positive; 9. pregnant or breasting-feeding women; 10. any situation that investigators regard not suitable for attending in this study or may affect the data analysis.

Keywords: multiple myeloma chimeric antigen receptor t cell bcma
a study of fluoxetine in major depressive disorder (mdd) long-term dosing

Conditions: Major Depressive Disorder

Summary: this study will evaluate the safety and effectiveness of fluoxetine flexible dosing in the treatment of mdd in adult japanese participants. participants who complete the short-term treatment phase of study b1y-je-hclv (nct#: nct01808612) will be allowed to enroll in this study, and receive fluoxetine treatment for an additional 52 weeks.


Eligibility criteria:
inclusion criteria: * have completed study b1y-je-hclv (nct#:nct01808612) * agree to abstain from sexual activity or to use a reliable method of birth control exclusion criteria: * significant suicidal risk * have a current or previous diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive disorder, or post-traumatic stress disorder * have a history of substance abuse or dependence within the past 6 months, excluding caffeine and nicotine * need to use thioridazine or pimozide during the study * have a positive urine drug screen for drugs with abuse potential * female participants who are either pregnant, nursing, or have recently given birth, or male participants who are planning for their partners to be or become pregnant * have frequent or severe allergic reactions to multiple medications * have a serious or unstable medical illness or condition, or psychological condition * participants deemed ineligible by the investigator or sub-investigator for other reasons
anatomical right posterior sectionectomy of the liver by ious-guided finger compression

Conditions: Colorectal Liver Metastases; Hepatocellular Carcinoma; Liver Malignancies

Summary: the use of intraoperative ultrasound (ious) allows us to perform new conservative hepatectomies. the investigators previously reported the systematic subsegmentectomy by ious-guided finger compression for segments 2-3, which is currently applied for patients with hepatocellular carcinoma (hcc)on cirrhosis. the investigators herein describe a novel technique, which consists in the systematic right posterior sectionectomy by ious-guided finger compression.

a novel technique for the demarcation of the resection area by means of ious-guided finger compression to accomplish a right posterior sectionectomy is described. dissection or encirclement of the sectional pedicles for resection area demarcation is thus avoided. ten patients underwent this technique successfully without mortality or major morbidity. ious-guided finger compression of sectional portal pedicle feeding the right posterior section is a feasible, safe, and effective method.

Eligibility criteria:
inclusion criteria: * patients with tumors at least at 1 cm distally to the bifurcation of the right portal vein (bifurcation of p5-8 and p6-7) eligible for right posterior sectionectomy, namely the anatomical removal of segment 6 and 7, were considered potential candidates to this procedure. precisely, these criteria were adopted: * patients with hepatocellular carcinoma (hcc) with infiltrative growing pattern in contact with p6-7; * patients with any type of hcc in contact with p6-7 with distal bile duct dilation; * patients with colorectal liver metastasis (clm) in contact with p6-7. exclusion criteria: * exclusion criteria for carrying out the herein described procedure was considered the presence of tumoral thrombosis in p6-7.

Keywords: colorectal liver metastasis hepatocellular carcinoma liver surgery intraoperative ultrasound finger-compression
motivational interviewing effect on reducing cardiovascular disease risk factors

Conditions: Cardiovascular Diseases; Motivation; Nurse's Role; Risk Reduction

Summary: aim: the aim of this study is to examine the effect of motivational interviewing-based training program on reducing cardiovascular disease risk factors in adults. methods: in the first stage, individuals' cvd risk levels were determined. in the second stage, a 6-session motivational interview-based training program was applied to the intervention group with a medium cvd risk level (hearthscore score between 2 and 5 points). brochures were distributed to the control group.

the aim of this study is to determine the cvd risks of adult individuals between the ages of 40-70 and to evaluate the effect of a motivational interview-based training program on reducing modifiable risk factors in individuals with moderate cvd risk. hypothesis; a 6-session motivational interview-based training program aimed at reducing cvd risk factors reduces the risk level in the intervention group more than the control group. this study will be carried out in 2 stages. in the first phase, risk prevalence screening will be carried out to determine the cvd risks of individuals between october and november 2023. in the 2nd phase, a randomized controlled study will be conducted to evaluate the intervention program for individuals at medium risk level (heartscore® between 2 and 5).

Eligibility criteria:
inclusion criteria: * being aged between 40 and 70 years, * being voluntary to participate in the study, exclusion criteria: * having a known and diagnosed cvd * not being voluntary to participate in the study.

Keywords: cardiovascular disease motivational interviewing risk reduction nurse's role
assessing the utility of mmpi-2-rf-ex in detecting simulated underreporting of current suicide risk in military veterans

Conditions: Suicidal Ideation; Suicidal

Summary: the aim of the current project are is examine the incremental predictive utility of the mmpi-2-rf-ex validity scales in detecting simulated underreporting of suicide risk on the mmpi-2-rf-ex and other self-report measures of suicide risk in 150 military veterans experiencing past-month death or suicidal ideation.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * us military veteran * death or suicidal ideation/suicide attempt within the past month exclusion criteria: * non-veteran status * acute intoxication or active psychosis precluding provision of informed consent * an inability to communicate and comprehend english * residence outside the united states * lack of past-month death/suicide ideation or attempt * younger than 18 years of age
evaluation of the extension at community level of safe male circumcision (anrs 12126 orange farm 2)

Conditions: HIV Infections

Summary: this study is aimed at demonstrating whether or not male circumcision can be used as an effective public health prevention tool that will have an impact on hiv prevalence in the south african population.

a randomized, controlled trial (anrs 1265) conducted in orange farm (south africa) has demonstrated that male circumcision (mc) can reduce the risk of hiv acquisition by more than 50% among young men. this result has been confirmed by two similar studies conducted in uganda and in kenya. giving these findings, the next logical step is to demonstrate whether or not mc can be used as an effective public health prevention tool that will have an impact on hiv in populations as well as among individuals. this research study aims to establish a mc intervention in the community where the first randomized controlled trial of the impact of mc on men's risk of acquiring hiv infection was carried out in order to evaluate its impact on: 1. knowledge, attitudes and practice regarding mc 2. existing means of prevention (sexual behavior change, condom use, sti treatment-seeking behavior and vct (voluntary counseling and testing) attendance) 3. the spread of hiv and hsv-2 this research will be carried out over a period of 60 months and will have three major components: (1) the delivery of the intervention, (2) quantitative studies (cross-sectional surveys), and (3) qualitative studies.

Eligibility criteria:
inclusion criteria: * being uncircumcised * living in orange farm (south africa) for more than 3 months * agreeing to follow the instructions given by doctors, nurses and/or staff, and in particular to abstain from sex for 6-weeks after being circumcised * having understood and sign a consent form written in their own language * for those younger than 18 years of age having a written authorization from one parent or guardian and having signed an assent form. exclusion criteria: * subjects with contraindications for male circumcision * allergy to anesthesia * hemophilia or bleeding disorders * genital ulceration or other symptoms of sexually transmitted infections * signs of infections or aids * abnormal genital anatomy * history of diabetes

Keywords: male circumcision hiv sexual behavior hiv prevention hiv seronegativity
in-hospital detection of elevated blood pressure

Conditions: Hypertension; Blood Pressure, High

Summary: the goal of this clinical trial is to analyse the prevalence of new or uncontrolled arterial hypertension (aht) after hospital discharge of medical in-patients with elevated blood pressure (bp) values during hospitalisation. the main questions it aims to answer are: * do elevated bp values during hospitalisation correspond to new or uncontrolled aht after hospital discharge? * is it safe to postpone adaption of antihypertensive treatment until after proper evaluation of aht after hospital discharge? participants will either be treated according to their physicians' decision or antihypertensive treatment adaptions will be postponed until after hospital discharge.


Eligibility criteria:
inclusion criteria: * patient hospitalized on the internal medicine ward for non-cardiovascular causes, i.e. patients hospitalized for conditions, which are not acutely worsened by uncontrolled aht * asymptomatic elevated bp values (defined as 140-180 mmhg systolic and/or 90-110 mmhg diastolic) on at least 2 occasions * ability to understand study procedures and to provide written informed consent exclusion criteria: * hospitalization for any conditions which can be worsened by uncontrolled aht: * cerebrovascular events * acute coronary syndrome * acute or decompensated heart failure * any condition preventing abpm * pregnant or lactating women * failure to provide informed consent

Keywords: arterial hypertension elevated blood pressure ambulatory blood pressure measurement antihypertensive medication
a study to learn about abrocitinib in adult patients with moderate to severe atopic dermatitis.

Conditions: Atopic Dermatitis; Eczema

Summary: the purpose of this study is to learn about the safety and effects of abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. atopic dermatitis, or ad, is a long-lasting disease that causes inflammation, redness, and irritation of the skin. this study is seeking participant who are older than 18 years with moderate-to-severe chronic ad. participants must have no underlying medical conditions that prevent them from taking abrocitinib. all participants in this study will receive abrocitinib as a tablet once daily. they can take abrocitinib and use medicated topical treatment for ad at the same time. we will examine the experiences of patients receiving the study medicine. this will help us determine if the study medicine is safe and helps in treating ad. participants will take part in this study for 24 months. during this time, they will visit the study clinic about 5 times (about 1 time every 4 to 6 months).


Eligibility criteria:
inclusion criteria: * patients older than 18 years of age at inclusion. * patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval. * patients that have been informed of the study procedures and have signed the consent. exclusion criteria: * patients for whom abrocitinib is contraindicated. * patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons. * patients not affiliated to the french social security system. * patients deprived of liberty, under guardianship, or unable to provide oral consent. * patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).

Keywords: atopic dermatitis ad eczema abrocitinib jak inhibitors france dermatitis atopic inflammatory disease dermatology
high-resolution assessment of extracranial plaques in a multiple centers evolocumab randomized study

Conditions: Cerebral Atherosclerosis

Summary: this study intends to explore the therapeutic effect of pcsk9i evolocumab on atherosclerotic plaques in cerebral arteries (including carotid and vertebral arteries) compared with intensive statin treatment, and monitor the pathological properties of carotid/vertebral artery plaques with oct technology. at the same time, three-dimensional ultrasound and high-resolution magnetic resonance are used to explore the new mechanism of pathological changes of cerebral atherosclerotic plaques in a multidimensional manner.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old, regardless of sex; 2. cerebrovascular angiography examination was performed, and the imaging characteristics were consistent with: 1) the stenosis degree of internal carotid artery (starting from c1 segment) or vertebral artery (starting from vertebral artery to v4 segment) was 20%-69%; 2) the target vessel for imaging has not undergone or intends to undergo revascularization and must be available for oct imaging catheter; 3. participants who understand and sign the informed consent form voluntarily. exclusion criteria: 1. intolerant to both atorvastatin and rosuvastatin; 2. history of major surgery or endovascular treatment within 3 months prior to the screening period; 3. arterial stenosis or occlusion not caused by atherosclerosis, such as arterial dissection, moya-moya disease, vasculitis, radiation vascular disease, or fibromuscular dysplasia; 4. abnormal liver function (alt \> 3 times the upper limit of normal); 5. renal dysfunction (glomerular filtration rate (egfr) \<45 ml/min/1.73m2 at screening); 6. thrombocytopenia (plt\<100g/l); 7. the expected survival time is not more than 6 months; 8. other known serious life-threatening disease (such as hematologic disease, malignancy), unstable vital signs or need for continuous monitoring, or moribund state during screening; 9. patients have been included in other studies that conflict with this study; 10. known sensitivity to any of the products or components to be administered during dosing; 11. pregnant, breastfeeding or planning pregnancy, and other conditions that the investigator considers the patient unsuitable for enrollment; 12. other conditions that the investigator considered inappropriate for enrollment.

Keywords: atherosclerosis plaque burden evolocumab high-resolution assessment oct
small bowel obstruction and surgery

Conditions: Acute Small Intestine Obstruction

Summary: postoperative management after small bowel obstruction (sbo) surgery is not consensual and better knowledge of risk factors for postoperative morbidity could help to add evidence of the feasibility of enhanced recovery programs (erps). in elective surgery, erps have shown a significant benefit for the patient but this is not performed routinely in emergency surgery due to the difficulty to avoid postoperative nasogastric tube. the aim was to identify risk factors for postoperative morbidity and for nasogastric tube (ngt) replacement after sbo surgery.


Eligibility criteria:
inclusion criteria: * surgical management of small bowel obstruction due to adhesions exclusion criteria: * obstruction not caused by single band adhesion * matted adhesions, or if they were less than 18 years old
neuromas as the cause of pain

Conditions: Neuropathic Pain; Neuroma

Summary: neuromas are frequent after trauma and surgery, including amputation and can be identified by high-resolution ultrasound. the role of neuromas as the cause of neuropathic pain is uncertain. the investigators therefore wish to explore if spontaneous and evoked pain will be relieved by injection of local anesthetics near painful neuromas in subjects with peripheral nerve injury.


Eligibility criteria:
inclusion criteria: * subjects with peripheral nerve injury 3 months prior to participation exclusion criteria: * severe somatic or psychiatric diseases * other peripheral neuropathy * lack of ability to cooperate to the clinical examination * allergy to lidocaine or similar analgetics